Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 152–153
HOS-214890 · Präparat HOS-155350
152 MedDRA system Very common Common adverse Uncommon adverse organ classes adverse reactions reactions reactions Vomiting (G3/4: 3%) Gastrointestinal haemorrhage (severe: 0.3%) Skin and subcutaneous Alopecia; tissue disorders Skin reaction (G3/4: 5.9%); Nail disorders (severe: 2.6%) Musculoskeletal and Myalgia Arthralgia connective tissue (severe: 1.4%) disorders General disorders and Fluid retention Infusion site reaction; administration site (severe: 6.5%); Non-cardiac chest pain conditions Asthenia (severe: 0.4%) (severe: 11.2%); Pain Investigations G3/4 Blood bilirubin increased (< 5%); G3/4 Blood alkaline phosphatase increased (< 4%);G3/4 AST increased (< 3%); G3/4 ALT increased (< 2%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage db0139c1fb3f340d7626b1059c2c9b0009c50011117c7ad3f87a5c10dceb572c · Zeichen 7585–9076 im Abschnitt